Table 3 Cost-effectiveness analyses by malaria species and type of analysis for a usual care setting

Plasmodium falciparum

 Per protocol (total = 186)

  Number

92

94

  Successes (proportion)

0.978

1.00

  Mean cost (US$)/patient

7.66

17.28

  Incremental successes

–

0.022

  Incremental costs (US$)

–

9.61

  Incremental cost-effectiveness ratio

–

436.82

 Modified intention to treat (N = 198)

  Number

100

98

  (i) Worst case

   Successes (proportion)

0.900

0.959

   Mean cost (US$)/patient

7.55

17.16

   Incremental successes

–

0.059

   Incremental costs (US$)

–

9.60

   Incremental cost-effectiveness ratio

–

162.71

  (ii) Best case

   Successes (proportion)

0.980

1.000

   Mean cost (US$)/patient

7.55

17.16

   Incremental successes

–

0.020

   Incremental costs (US$)

–

9.60

   Incremental cost-effectiveness ratio

–

480.00

Plasmodium vivax

 Per protocol (total = 46)

  Number

20

26

  Successes (proportion)

0.300

1.000

  Mean cost (US$)/patient

7.41

17.78

  Incremental successes

–

0.700

  Incremental costs (US$)

–

10.38

  Incremental cost-effectiveness ratio

–

14.83

  Modified intention to treat (N = 47)

  Number

20

27

  (i) Worst case

   Successes (proportion)

0.300

0.963

   Mean cost (US$)/patient

7.41

17.52

   Incremental successes

–

0.663

   Incremental costs (US$)

–

10.11

   Incremental cost-effectiveness ratio

–

15.25

  (ii) Best case

   Successes (proportion)

0.300

1.000

   Mean cost (US$)/patient

7.41

17.52

   Incremental successes

–

0.700

   Incremental costs (US$)

–

10.11

   Incremental cost-effectiveness ratio

–

14.29